MedPath

Transdermal testosterone supplementation in elderly hypogonadal men with sarcopenia: effects on muscle function, physical performance, body composition and quality of life.”A randomized, double-blind, placebo-control, parallel-group study on 150 patients.

Phase 1
Conditions
ELDERLY HYPOGONADAL MEN WITH SARCOPENIA
MedDRA version: 9.1Level: LLTClassification code 10063024Term: Sarcopenia
Registration Number
EUCTR2006-006354-98-FR
Lead Sponsor
PIERRE FABRE MEDICAMENT
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Male
Target Recruitment
150
Inclusion Criteria

- elderly men aged between 65 and 90 years
- AMS ³ 37
- Serum BT < 0.90 ng/mL
- Short Physical Performance Battery (SPPB) value between 4 and 9
- Body lean mass evaluation by Impedancemetry < -2 DS from normal value
- Serum total PSA £ 3 ng/mL
- Able to complete an informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Known acute or chronic prostate pathology, and/or PSA > 3 ng/mL, and/or suspicion of prostate cancer; familial history of prostate cancer
- Male breast cancer
- Severe cardiovascular, respiratory, hepatic, renal failure, or metabolic diseases/disorders
- Unstable angina, NYHA class III or IV congestive heart failure, or myocardial infarction within 3 months of entry
- Blood pressure > 160/90 mm Hg
- Hematocrit > 48%
- ALT and/or AST twice above the upper limit
- Uncontrolled hyper or hypothyroidism
- Limiting neuromuscular, joint or bone disease
- Documented sleep apnea
- Dementia, cognitive impairment or any psychiatric disease affecting subject’s ability to provide informed consent
- Rheumatoid arthritis, cirrhosis or active hepatitis
- History of stroke causing persistent motor deficit
- Uncontroled diabetic patients (type I or II)
- Acute illness in the prior 30 days
- Severe disability limiting strength or physical function testing
- Inability to perform hang-grip test
- Generalized dermatological disorders that might affect testosterone absorption or local tolerability assessment (hypertrichosis, psoriasis, eczema)

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath